Open Access18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients
Author(s) -
Patricia de Crémoux,
Lucie Biard,
Brigitte Poirot,
Philippe Bertheau,
Luis Teixeira,
Jacqueline Lehmann-Che,
Fatiha Bouhidel,
Pascal Merlet,
Marc Espié,
Matthieu RescheRigon,
Christos Sotiriou,
David Groheux
Publication year - 2018
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.24674
Subject(s) - medicine , breast cancer , chemotherapy , oncology , neoadjuvant therapy , positron emission tomography , standardized uptake value , surrogate endpoint , biopsy , pathological , cancer , radiology
The efficacy of neoadjuvant chemotherapy regimens in advanced luminal breast cancer patients is difficult to predict. Intrinsic properties of breast tumors, including altered gene expression profile and dynamic evaluation of metabolic properties of tumor cells using positron emission tomography/computed tomography (PET/CT) of tumor cells, have been identified to guide patient's prognosis. The aim of this study is to determine if both analyses may improve the prediction of response to neoadjuvant chemotherapy in ER-positive / HER2-negative breast cancers (BCs) patients.